The relationship between serum neopterin levels and disease activity in patients with spondyloarthropathy.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2026-06-01 Epub Date: 2026-06-21 DOI:10.1080/17520363.2026.2686306

Ayza Kılıç, Rezan Koçak Ulucaköy, Zakir Osmanov, İdil Melis Çobanoğlu, Cemalettin Aybay, Feride Nur Göğüş

{"title":"The relationship between serum neopterin levels and disease activity in patients with spondyloarthropathy.","authors":"Ayza Kılıç, Rezan Koçak Ulucaköy, Zakir Osmanov, İdil Melis Çobanoğlu, Cemalettin Aybay, Feride Nur Göğüş","doi":"10.1080/17520363.2026.2686306","DOIUrl":null,"url":null,"abstract":"Objective: Biomarkers that accurately reflect disease activity and inflammatory burden are needed, particularly in the early stages of spondyloarthropathy (SpA). This study aimed to evaluate the association between serum neopterin levels and disease activity indices in patients with SpA.Methods: This cross-sectional study included 84 participants based on a priori sample size estimation: 21 patients with axial SpA (axSpA), 21 with peripheral SpA (pSpA), 21 with active rheumatoid arthritis (RA) and 21 healthy controls (HC). Disease activity in SpA was assessed using the Axial Spondyloarthritis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). A disease activity was assessed using the Disease Activity Score in 28 Joints (DAS28). Serum neopterin levels were measured by Enzyme-Linked Immunosorbent Assay.Results: Serum neopterin levels differed significantly among the groups (post-hoc, p = 0.007), with higher levels observed in patients with active RA than in those with axSpA, and no significant associations were found between neopterin levels and disease activity indices in either axial or peripheral SpA.Conclusion: In the present study cohort, no significant association was observed between serum neopterin levels and disease activity in patients with axial or peripheral SpA.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"511-518"},"PeriodicalIF":2.1000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432832/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2686306","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Biomarkers that accurately reflect disease activity and inflammatory burden are needed, particularly in the early stages of spondyloarthropathy (SpA). This study aimed to evaluate the association between serum neopterin levels and disease activity indices in patients with SpA.

Methods: This cross-sectional study included 84 participants based on a priori sample size estimation: 21 patients with axial SpA (axSpA), 21 with peripheral SpA (pSpA), 21 with active rheumatoid arthritis (RA) and 21 healthy controls (HC). Disease activity in SpA was assessed using the Axial Spondyloarthritis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). A disease activity was assessed using the Disease Activity Score in 28 Joints (DAS28). Serum neopterin levels were measured by Enzyme-Linked Immunosorbent Assay.

Results: Serum neopterin levels differed significantly among the groups (post-hoc, p = 0.007), with higher levels observed in patients with active RA than in those with axSpA, and no significant associations were found between neopterin levels and disease activity indices in either axial or peripheral SpA.

Conclusion: In the present study cohort, no significant association was observed between serum neopterin levels and disease activity in patients with axial or peripheral SpA.

查看原文本刊更多论文

脊柱关节病患者血清新蝶呤水平与疾病活动度的关系。

目的：准确反映疾病活动性和炎症负担的生物标志物是必要的，特别是在脊椎关节病（SpA）的早期阶段。本研究旨在评估SpA患者血清新蝶呤水平与疾病活动度指标之间的关系。方法：基于先验样本量估计，本横断面研究纳入84名参与者：21例轴向SpA （axSpA）患者，21例外周SpA （pSpA）患者，21例活动性类风湿关节炎（RA）患者和21例健康对照（HC）。SpA患者的疾病活动性采用轴性脊柱炎疾病活动性评分（ASDAS）和浴缸强直性脊柱炎疾病活动性指数（BASDAI）进行评估。使用28个关节疾病活动度评分（DAS28）评估疾病活动度。采用酶联免疫吸附法测定血清新蝶呤水平。结果：各组血清新蝶呤水平差异显著（事后，p = 0.007），活动性RA患者血清新蝶呤水平高于axSpA患者，且在轴向或外周SpA患者血清新蝶呤水平与疾病活动性指数之间未发现显著关联。结论：在本研究队列中，未观察到血清新蝶呤水平与轴向或外周SpA患者疾病活动度之间的显著关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.